Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RVNC
  • CUSIP: N/A
  • Web:
  • Market Cap: $664.49 million
  • Outstanding Shares: 30,273,000
Average Prices:
  • 50 Day Moving Avg: $20.85
  • 200 Day Moving Avg: $20.01
  • 52 Week Range: $12.35 - $24.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.40
  • P/E Growth: -0.50
Sales & Book Value:
  • Annual Revenue: $300,000.00
  • Price / Sales: 2,214.97
  • Book Value: $5.93 per share
  • Price / Book: 3.70
  • EBIDTA: ($85,040,000.00)
  • Net Margins: -28,187.33%
  • Return on Equity: -37.31%
  • Return on Assets: -33.87%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.92%
  • Quick Ratio: 11.92%
  • Average Volume: 187,855 shs.
  • Beta: 1.7
  • Short Ratio: 19.71

Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.94) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.10. The business earned $0.08 million during the quarter, compared to analysts' expectations of $0.07 million. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. The business's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.71) EPS. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

5 brokers have issued 1 year target prices for Revance Therapeutics' stock. Their forecasts range from $22.00 to $55.00. On average, they anticipate Revance Therapeutics' stock price to reach $37.00 in the next year. View Analyst Ratings for Revance Therapeutics.

What are analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (5/9/2017)
  • 2. Aegis analysts commented, "We spoke with management this morning to which they mentioned they do not expect a material increase in research and development costs in association with the trial site expansion." (5/1/2017)

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:

  • Angus Charles Russell, Independent Chairman of the Board
  • Dan L. Browne, Co-Founder, President, Chief Executive Officer, Director
  • Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer
  • Abhay Joshi Ph.D., Chief Operating Officer
  • Curtis L. Ruegg Ph.D., Executive Vice President of Research and Development
  • Sharon Hall, Vice President of Regulatory Affairs
  • Jeanie D. Herbert, Senior Director of Investor Relations
  • Julian S. Gangolli, Director
  • Phil J. Vickers, Director
  • Robert F. Byrnes, Independent Director

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (11.80%), Wellington Management Group LLP (7.13%), Bank of New York Mellon Corp (6.20%), Vanguard Group Inc. (2.96%), Canada Pension Plan Investment Board (1.99%) and Goldman Sachs Group Inc. (1.87%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg, L Daniel Browne and Lauren P Silvernail. View Institutional Ownership Trends for Revance Therapeutics.

Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?

Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Wellington Management Group LLP, Morgan Stanley, Wells Fargo & Company MN, Suffolk Capital Management LLC, Credit Suisse AG, Rothschild Asset Management Inc. and ProShare Advisors LLC. Company insiders that have sold Revance Therapeutics stock in the last year include Curtis Ruegg, L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Vanguard Group Inc., Victory Capital Management Inc., Acadian Asset Management LLC, JPMorgan Chase & Co. and Geode Capital Management LLC. View Insider Buying and Selling for Revance Therapeutics.

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of Revance Therapeutics stock can currently be purchased for approximately $21.95.

MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $37.00 (68.56% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017AegisReiterated RatingBuy$28.00 -> $36.00LowView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00N/AView Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00 -> $35.00N/AView Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00N/AView Rating Details
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Revance Therapeutics (NASDAQ:RVNC)
Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Earnings History by Quarter for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.85)($0.80)($0.83)
Q2 20172($0.99)($0.98)($0.99)
Q3 20172($1.02)($1.02)($1.02)
Q4 20172($0.99)($0.95)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 31.15%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.60View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : May 26, 2017 - May 27 at 4:06 AM logoRevance Therapeutics Inc (RVNC) CEO L Daniel Browne Sells 19,713 Shares - May 24 at 10:57 PM logoRevance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 1,793 Shares - May 24 at 10:56 PM logoRevance Therapeutics Inc (RVNC) CEO Sells $248,197.40 in Stock - May 24 at 10:56 PM logoRevance Therapeutics (RVNC) Presents On Phase 2 Cervical Dystonia 24-Week Results - Slideshow - May 23 at 7:01 PM logoRevance Therapeutics Inc (RVNC) Stock Rating Reaffirmed by Aegis - May 19 at 9:36 PM logoRevance Therapeutics Inc (RVNC) Receives Average Recommendation of "Buy" from Brokerages - May 19 at 7:30 PM logoRevance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial - May 19 at 12:32 PM logoETFs with exposure to Revance Therapeutics, Inc. : May 15, 2017 - May 15 at 6:50 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : May 15, 2017 - May 15 at 9:32 AM logoSunTrust Banks Weighs in on Revance Therapeutics Inc's Q2 2017 Earnings (RVNC) - May 15 at 7:28 AM logoRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 11:00 PM logoQ2 2017 Earnings Estimate for Revance Therapeutics Inc Issued By William Blair (RVNC) - May 12 at 8:34 AM logoRevance Therapeutics Inc (RVNC) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS - May 10 at 6:58 PM logoEdited Transcript of RVNC earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 11:06 AM logoInvestor Network: Revance Therapeutics, Inc. to Host Earnings Call - May 9 at 7:10 PM logoRevance Releases First Quarter 2017 Results - May 9 at 7:10 PM logoRevance reports 1Q loss - May 9 at 7:10 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : May 5, 2017 - May 5 at 7:57 PM logoRevance Therapeutics (RVNC) Earns Daily Coverage Optimism Score of 0.01 - May 3 at 2:12 PM logoRevance Therapeutics Inc (RVNC) Earns "Buy" Rating from Aegis - May 1 at 4:14 PM logoRevance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis - May 1 at 10:01 AM logoRevance Therapeutics (RVNC) Earns Daily News Sentiment Score of 0.19 - April 30 at 8:23 AM logoFavorable Media Coverage Extremely Likely to Impact Revance Therapeutics (RVNC) Stock Price - April 26 at 12:30 PM logoRevance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017 - April 25 at 6:40 PM logoRevance Therapeutics Inc (RVNC) Given Average Rating of "Buy" by Analysts - April 24 at 9:44 PM logoSomewhat Favorable News Coverage Somewhat Likely to Impact Revance Therapeutics (RVNC) Share Price - April 23 at 9:17 PM logoRevance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : April 20, 2017 - April 20 at 7:42 PM logoVery Favorable News Coverage Very Unlikely to Affect Revance Therapeutics (RVNC) Stock Price - April 19 at 10:29 AM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : April 19, 2017 - April 19 at 9:29 AM logoCommit To Buy Revance Therapeutics At $17.50, Earn 13.3% Annualized Using Options - April 7 at 12:22 PM logoRevance Therapeutics Inc (RVNC) Given Consensus Recommendation of "Buy" by Brokerages - March 29 at 12:55 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - March 15 at 8:53 AM logoRevance Therapeutics (RVNC) Presents At Cowen and Company 37th Annual Health Care Conference - March 8 at 7:52 PM logoRevance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines - March 7 at 9:21 AM logoREVANCE THERAPEUTICS, INC. Financials - March 4 at 7:33 PM logoRevance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting - March 3 at 8:13 AM logoEdited Transcript of RVNC earnings conference call or presentation 27-Feb-17 9:30pm GMT - March 2 at 12:55 AM logoREVANCE THERAPEUTICS, INC. Files SEC form 10-K, Annual Report - February 28 at 7:18 PM logoRevance Releases Fourth Quarter and Full Year 2016 Results - February 27 at 4:27 PM logoQ4 2016 Revance Therapeutics Inc Earnings Release - After Market Close - February 27 at 9:25 AM logoRevance to Participate in Upcoming Investor Conferences - February 22 at 7:49 PM logoRevance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017 - February 16 at 7:18 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - February 8 at 11:44 PM logoBELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 - January 27 at 2:34 AM logoRevance Presents Clinical Data for RT002 Injectable at TOXINS 2017 - January 18 at 9:03 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events - January 12 at 9:01 PM logoRevance Therapeutics (RVNC) Offers FY17 Outlook - - January 8 at 12:20 AM logoRevance Therapeutics (RVNC) Offers FY17 Outlook - January 6 at 3:23 AM logoRevance Provides Clinical Milestones and Financial Outlook for 2017 - January 6 at 3:23 AM



Revance Therapeutics (RVNC) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff